Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.

Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER.

Sci Rep. 2019 Jun 14;9(1):8721. doi: 10.1038/s41598-019-44365-2.

2.

First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial.

Funes CJ, Mace RA, Macklin EA, Plotkin SR, Jordan JT, Vranceanu AM.

J Neurooncol. 2019 Jul;143(3):505-513. doi: 10.1007/s11060-019-03182-3. Epub 2019 May 2.

PMID:
31049826
3.

First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.

Rauen KA, Alsaegh A, Ben-Shachar S, Berman Y, Blakeley J, Cordeiro I, Elgersma Y, Evans DG, Fisher MJ, Frayling IM, George J, Huson SM, Kerr B, Khire U, Korf B, Legius E, Messiaen L, van Minkelen R, Nampoothiri S, Ngeow J, Parada LF, Phadke S, Pillai A, Plotkin SR, Puri R, Raji A, Ramesh V, Ratner N, Shankar SP, Sharda S, Tambe A, Vikkula M, Widemann BC, Wolkenstein P, Upadhyaya M.

Am J Med Genet A. 2019 Jun;179(6):1091-1097. doi: 10.1002/ajmg.a.61125. Epub 2019 Mar 25.

PMID:
30908877
4.

A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.

Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, Ng MR, Chen JW, Zhang N, Zhao Y, Gao X, Fujita T, Roberge S, Huang P, Jain RK, Plotkin SR, Stankovic KM, Xu L.

Nat Protoc. 2019 Feb;14(2):541-555. doi: 10.1038/s41596-018-0105-7.

PMID:
30617350
5.

Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.

Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER.

Sci Rep. 2018 Nov 20;8(1):17062. doi: 10.1038/s41598-018-34820-x. Erratum in: Sci Rep. 2019 Jun 14;9(1):8721.

6.

Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial.

Vranceanu AM, Zale EL, Funes CJ, Macklin EA, McCurley J, Park ER, Jordan JT, Lin A, Plotkin SR.

JMIR Res Protoc. 2018 Oct 23;7(10):e11008. doi: 10.2196/11008.

7.

Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.

Merker VL, Dai A, Radtke HB, Knight P, Jordan JT, Plotkin SR.

BMC Health Serv Res. 2018 Aug 29;18(1):668. doi: 10.1186/s12913-018-3471-5.

8.

Benign Intracranial Tumors.

Jordan JT, Plotkin SR.

Neurol Clin. 2018 Aug;36(3):501-516. doi: 10.1016/j.ncl.2018.04.007. Review.

PMID:
30072068
9.

Considerations for development of therapies for cutaneous neurofibroma.

Verma SK, Riccardi VM, Plotkin SR, Weinberg H, Anderson RR, Blakeley JO, Jarnagin K, Lee J.

Neurology. 2018 Jul 10;91(2 Supplement 1):S21-S30. doi: 10.1212/WNL.0000000000005791.

PMID:
29987132
10.

Cutaneous neurofibromas: Current clinical and pathologic issues.

Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, Miller DC, Huson S, Peltonen J, Rosenberg A, Carroll SL, Verma SK, Mautner V, Upadhyaya M, Stemmer-Rachamimov A.

Neurology. 2018 Jul 10;91(2 Supplement 1):S5-S13. doi: 10.1212/WNL.0000000000005792.

PMID:
29987130
11.

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.

Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium .

Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046.

PMID:
29982664
12.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN.

PLoS One. 2018 Jun 13;13(6):e0197350. doi: 10.1371/journal.pone.0197350. eCollection 2018.

13.

Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.

Huang V, Bergner AL, Halpin C, Merker VL, Sheridan MR, Widemann BC, Blakeley JO, Plotkin SR.

Otol Neurotol. 2018 Jun;39(5):632-638. doi: 10.1097/MAO.0000000000001781.

PMID:
29649040
14.

Neurofibromatosis and Schwannomatosis.

Plotkin SR, Wick A.

Semin Neurol. 2018 Feb;38(1):73-85. doi: 10.1055/s-0038-1627471. Epub 2018 Mar 16. Review.

PMID:
29548054
15.

Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.

Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, Zhao F, Zhao Y, Zhang Y, Zhang J, Fujita T, Stemmer-Rachamimov A, Ferraro GB, Liu H, Muzikansky A, Plotkin SR, Stankovic KM, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2077-E2084. doi: 10.1073/pnas.1719966115. Epub 2018 Feb 9.

16.

Pain correlates with germline mutation in schwannomatosis.

Jordan JT, Smith MJ, Walker JA, Erdin S, Talkowski ME, Merker VL, Ramesh V, Cai W, Harris GJ, Bredella MA, Seijo M, Suuberg A, Gusella JF, Plotkin SR.

Medicine (Baltimore). 2018 Feb;97(5):e9717. doi: 10.1097/MD.0000000000009717.

17.

Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848.

Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, Hsiao MC, Chen Z, Balasubramanian M, Barnett CP, Becker TA, Ben-Shachar S, Bertola DR, Blakeley JO, Burkitt-Wright EMM, Callaway A, Crenshaw M, Cunha KS, Cunningham M, D'Agostino MD, Dahan K, De Luca A, Destrée A, Dhamija R, Eoli M, Evans DGR, Galvin-Parton P, George-Abraham JK, Gripp KW, Guevara-Campos J, Hanchard NA, Hernández-Chico C, Immken L, Janssens S, Jones KJ, Keena BA, Kochhar A, Liebelt J, Martir-Negron A, Mahoney MJ, Maystadt I, McDougall C, McEntagart M, Mendelsohn N, Miller DT, Mortier G, Morton J, Pappas J, Plotkin SR, Pond D, Rosenbaum K, Rubin K, Russell L, Rutledge LS, Saletti V, Schonberg R, Schreiber A, Seidel M, Siqveland E, Stockton DW, Trevisson E, Ullrich NJ, Upadhyaya M, van Minkelen R, Verhelst H, Wallace MR, Yap YS, Zackai E, Zonana J, Zurcher V, Claes K, Martin Y, Korf BR, Legius E, Messiaen LM.

Am J Hum Genet. 2018 Jan 4;102(1):69-87. doi: 10.1016/j.ajhg.2017.12.001. Epub 2017 Dec 28.

18.

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.

Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT.

NPJ Precis Oncol. 2017;1. pii: 20. doi: 10.1038/s41698-017-0020-3. Epub 2017 Jun 12.

19.

Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT.

Merker VL, McDannold S, Riklin E, Talaei-Khoei M, Sheridan MR, Jordan JT, Plotkin SR, Vranceanu AM.

J Neurooncol. 2018 Jan;136(2):335-342. doi: 10.1007/s11060-017-2657-8. Epub 2017 Nov 8.

PMID:
29119424
20.

Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods.

Cai W, Steinberg SM, Bredella MA, Basinsky G, Somarouthu B, Plotkin SR, Solomon J, Widemann BC, Harris GJ, Dombi E.

Acad Radiol. 2018 Feb;25(2):144-152. doi: 10.1016/j.acra.2017.09.004. Epub 2017 Oct 31.

21.

Anti-VEGF treatment improves neurological function in tumors of the nervous system.

Zhang N, Chen J, Ferraro GB, Wu L, Datta M, Jain RK, Plotkin SR, Stemmer-Rachamimov A, Xu L.

Exp Neurol. 2018 Jan;299(Pt B):326-333. doi: 10.1016/j.expneurol.2017.09.008. Epub 2017 Sep 11. Review.

PMID:
28911884
22.

First report of factors associated with satisfaction in patients with neurofibromatosis.

Riklin E, Talaei-Khoei M, Merker VL, Sheridan MR, Jordan JT, Plotkin SR, Vranceanu AM.

Am J Med Genet A. 2017 Mar;173(3):671-677. doi: 10.1002/ajmg.a.38079.

PMID:
28211981
23.

First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.

Talaei-Khoei M, Riklin E, Merker VL, Sheridan MR, Jordan JT, Plotkin SR, Vranceanu AM.

J Neurooncol. 2017 Jan;131(2):413-419. doi: 10.1007/s11060-016-2314-7. Epub 2016 Nov 29.

PMID:
27900643
24.

Creation of an international registry to support discovery in schwannomatosis.

Ostrow KL, Bergner AL, Blakeley J, Evans DG, Ferner R, Friedman JM, Harris GJ, Jordan JT, Korf B, Langmead S, Leschziner G, Mautner V, Merker VL, Papi L, Plotkin SR, Slopis JM, Smith MJ, Stemmer-Rachamimov A, Yohay K, Belzberg AJ.

Am J Med Genet A. 2017 Feb;173(2):407-413. doi: 10.1002/ajmg.a.38024. Epub 2016 Oct 19.

PMID:
27759912
25.

Current status and recommendations for biomarkers and biobanking in neurofibromatosis.

Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR; REiNS International Collaboration.

Neurology. 2016 Aug 16;87(7 Suppl 1):S40-8. doi: 10.1212/WNL.0000000000002932.

26.

Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.

Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO; Whole Body MRI Committee for the REiNS International Collaboration; REiNS International Collaboration Members 2016.

Neurology. 2016 Aug 16;87(7 Suppl 1):S31-9. doi: 10.1212/WNL.0000000000002929.

27.

Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.

Plotkin SR, Davis SD, Robertson KA, Akshintala S, Allen J, Fisher MJ, Blakeley JO, Widemann BC, Ferner RE, Marcus CL; REiNS International Collaboration.

Neurology. 2016 Aug 16;87(7 Suppl 1):S13-20. doi: 10.1212/WNL.0000000000002933.

28.

Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT.

Vranceanu AM, Riklin E, Merker VL, Macklin EA, Park ER, Plotkin SR.

Neurology. 2016 Aug 23;87(8):806-14. doi: 10.1212/WNL.0000000000003005. Epub 2016 Jul 22.

PMID:
27449066
29.

The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway.

Stevenson DA, Schill L, Schoyer L, Andresen BS, Bakker A, Bayrak-Toydemir P, Burkitt-Wright E, Chatfield K, Elefteriou F, Elgersma Y, Fisher MJ, Franz D, Gelb BD, Goriely A, Gripp KW, Hardan AY, Keppler-Noreuil KM, Kerr B, Korf B, Leoni C, McCormick F, Plotkin SR, Rauen KA, Reilly K, Roberts A, Sandler A, Siegel D, Walsh K, Widemann BC.

Am J Med Genet A. 2016 Aug;170(8):1959-66. doi: 10.1002/ajmg.a.37723. Epub 2016 May 7.

30.

Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History Study.

Merker VL, Bergner AL, Vranceanu AM, Muzikansky A, Slattery W 3rd, Plotkin SR.

Otol Neurotol. 2016 Jun;37(5):574-9. doi: 10.1097/MAO.0000000000001019.

PMID:
27050651
31.

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR.

J Clin Oncol. 2016 May 10;34(14):1669-75. doi: 10.1200/JCO.2015.64.3817. Epub 2016 Mar 14.

32.

Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Blakeley JO, Plotkin SR.

Neuro Oncol. 2016 May;18(5):624-38. doi: 10.1093/neuonc/nov200. Epub 2016 Feb 6. Review.

33.

Laryngeal Manifestations of Neurofibromatosis.

Naunheim MR, Plotkin SR, Franco RA, Song PC.

Otolaryngol Head Neck Surg. 2016 Mar;154(3):494-7. doi: 10.1177/0194599815626133. Epub 2016 Jan 19.

PMID:
26786267
34.

Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1: Population-Based Approach.

Terry AR, Jordan JT, Schwamm L, Plotkin SR.

Stroke. 2016 Jan;47(1):60-5. doi: 10.1161/STROKEAHA.115.011406. Epub 2015 Dec 8.

PMID:
26645253
35.

Glioblastoma care in the elderly.

Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR.

Cancer. 2016 Jan 15;122(2):189-97. doi: 10.1002/cncr.29742. Epub 2015 Nov 30. Review.

36.

Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.

Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14676-81. doi: 10.1073/pnas.1512570112. Epub 2015 Nov 9.

37.

Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.

Farschtschi S, Merker VL, Wolf D, Schuhmann M, Blakeley J, Plotkin SR, Hagel C, Mautner VF.

Acta Neurol Scand. 2016 Jun;133(6):475-80. doi: 10.1111/ane.12490. Epub 2015 Sep 15.

PMID:
26369495
38.

A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.

Beauchamp RL, James MF, DeSouza PA, Wagh V, Zhao WN, Jordan JT, Stemmer-Rachamimov A, Plotkin SR, Gusella JF, Haggarty SJ, Ramesh V.

Oncotarget. 2015 Jul 10;6(19):16981-97.

39.

Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.

Stivaros SM, Stemmer-Rachamimov AO, Alston R, Plotkin SR, Nadol JB, Quesnel A, O'Malley J, Whitfield GA, McCabe MG, Freeman SR, Lloyd SK, Wright NB, Kilday JP, Kamaly-Asl ID, Mills SJ, Rutherford SA, King AT, Evans DG.

J Med Genet. 2015 Aug;52(8):557-62. doi: 10.1136/jmedgenet-2015-103050. Epub 2015 Jun 23.

40.

A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.

Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S.

Oncotarget. 2015 Feb 28;6(6):4527-36.

41.

Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system.

Terry AR, Merker VL, Barker FG 2nd, Leffert L, Bateman BT, Souter I, Plotkin SR.

Am J Obstet Gynecol. 2015 Jul;213(1):108-109. doi: 10.1016/j.ajog.2015.02.013. Epub 2015 Feb 14. No abstract available.

PMID:
25687565
42.

Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature.

Vranceanu AM, Merker VL, Park ER, Plotkin SR.

J Neurooncol. 2015 Apr;122(2):219-28. doi: 10.1007/s11060-015-1725-1. Epub 2015 Feb 7. Review.

PMID:
25663248
43.

Examining perceived cancer risk among patients with neurofibromatosis type 1.

Park ER, Smith KB, Merker VL, Muzikansky A, Vranceanu AM, Wang DL, Plotkin SR.

J Neurooncol. 2015 Mar;122(1):127-33. doi: 10.1007/s11060-014-1689-6. Epub 2015 Jan 6.

PMID:
25559686
44.

Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1.

Merker VL, Murphy TP, Hughes JB, Muzikansky A, Hughes MR, Souter I, Plotkin SR.

Fertil Steril. 2015 Mar;103(3):761-8.e1. doi: 10.1016/j.fertnstert.2014.11.021. Epub 2014 Dec 31.

PMID:
25557241
45.

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY.

Neurology. 2015 Jan 20;84(3):280-6. doi: 10.1212/WNL.0000000000001153. Epub 2014 Dec 19.

46.

Update from the 2013 International Neurofibromatosis Conference.

Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC.

Am J Med Genet A. 2014 Dec;164A(12):2969-78. doi: 10.1002/ajmg.a.36754. Epub 2014 Sep 24. No abstract available.

47.

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A.

Neuro Oncol. 2015 Jan;17(1):116-21. doi: 10.1093/neuonc/nou148. Epub 2014 Aug 6.

48.

The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.

Vranceanu AM, Merker VL, Plotkin SR, Park ER.

J Neurooncol. 2014 Oct;120(1):103-9. doi: 10.1007/s11060-014-1522-2. Epub 2014 Jul 15.

PMID:
25022450
49.

Teaching NeuroImages: brain mass with hilar adenopathy: the importance of histologic diagnosis.

Jordan JT, Yang HS, Narendra D, Plotkin SR.

Neurology. 2014 May 6;82(18):e161-2. doi: 10.1212/WNL.0000000000000393.

PMID:
24799521
50.

Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients.

Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1197-204. doi: 10.1007/s00280-014-2456-2. Epub 2014 Apr 8.

PMID:
24710627

Supplemental Content

Loading ...
Support Center